Bio-Rad
GenomeWeb Index Gains Slightly in July as Fluidigm, PerkinElmer, Bio-Rad Post Strong Increases
The GenomeWeb Index outperformed the Dow Jones, Nasdaq, and Nasdaq Biotechnology Index last month.
Bio-Rad Laboratories Q2 Revenues Climb 33 Percent, Beat Estimates
The firm saw growth across both its life science and clinical diagnostics businesses due to gradual recovery from the pandemic and increased its guidance for 2021.
Bio-Rad Laboratories, 10x Genomics Settle IP Lawsuits, Sign Global Cross-Licensing Agreement
With the settlement, which calls for dismissal of all single-cell IP lawsuits between the firms in several venues, one of the bitterest legal battles in biotech should come to an end.
Bio-Rad Laboratories Gets CE Mark for SARS-CoV-2, Influenza RT-PCR Assay Kit
The kit simultaneously detects the N gene of SARS-CoV-2 as well as influenza A and B targets in a single reaction.
Bio-Rad Laboratories, Stilla Technologies Settle IP Lawsuit
Bio-Rad had alleged Stilla's Naica digital PCR system infringed on four patents held or licensed by the firm.
Apr 29, 2021
Bio-Rad Q1 Revenues Rise 27 Percent, Beat Estimates
Mar 11, 2021
Feb 12, 2021
Oct 29, 2020
Bio-Rad Q3 Revenues Jump 15 Percent
Aug 17, 2020